|
|
|
|
Vol. 60, Issue 4, 797-807, October 2001
Department of Physiology and Biophysics, State University of New
York (SUNY) at Stony Brook, and Department of Anesthesiology, Health
Sciences Center at SUNY Stony Brook, Stony Brook, New York
Competitive antagonists to nicotinic acetylcholine receptors are
clinically used as muscle relaxants. Previously, we reported the
kinetics of inhibition (in the absence of acetylcholine) by (+)-tubocurarine and pancuronium on embryonic receptors. Here, we
examine cisatracurium, a commonly used muscle relaxant.
Outside-out patches were equilibrated with cisatracurium before
application of 300 µM acetylcholine. cisatracurium inhibited the
initial peak current, but the decay of these currents displayed a
pronounced biphasic behavior. The IC50 value was 54 ± 2 nM and 115 ± 4 nM for adult and embryonic receptors,
respectively. We designed a rapid perfusion system to apply or remove
cisatracurium for various times before application of acetylcholine. We
determined the association (embryonic, 3.4 ± 0.4 × 108 M
1 s
1; adult, 1.8 ± 0.3 × 108 M
1 s
1) and
dissociation (embryonic, 34 ± 6/s; adult: 13 ± 5/s) rates for cisatracurium. Association was 2.9- and 1.3-fold greater than that
of (+)-tubocurarine and pancuronium, respectively. Dissociation was 6- and 16-fold higher than (+)-tubocurarine and pancuronium, respectively.
These measurements correspond to dissociation of cisatracurium from
receptors in the absence of acetylcholine. Physiologically,
acetylcholine interacts with receptors equilibrated with antagonist. We
developed a mathematical technique that removes the effect of
desensitization and determined dissociation (embryonic, 52 ± 9/s;
adult, 33 ± 5/s) in the presence of acetylcholine. These data
suggest that presence of acetylcholine on one binding site of the
receptor increases the dissociation rate of antagonist from the other
binding site. We incorporated all of these rates into a computer
simulation of a comprehensive 11-state Markov model. There was
excellent agreement (without curve fitting) between simulated and
experimental currents.
This article has been cited by other articles:
![]() |
M. Liu and J. P. Dilger Site Selectivity of Competitive Antagonists for the Mouse Adult Muscle Nicotinic Acetylcholine Receptor Mol. Pharmacol., January 1, 2009; 75(1): 166 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liu and J. P. Dilger Synergy Between Pairs of Competitive Antagonists at Adult Human Muscle Acetylcholine Receptors Anesth. Analg., August 1, 2008; 107(2): 525 - 533. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Demazumder and J. P. Dilger The kinetics of competitive antagonism of nicotinic acetylcholine receptors at physiological temperature J. Physiol., February 15, 2008; 586(4): 951 - 963. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Ford, M. Matchett, J. E. Krause, and W. Yu The P2X3 Antagonist P1, P5-Di[inosine-5'] Pentaphosphate Binds to the Desensitized State of the Receptor in Rat Dorsal Root Ganglion Neurons J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 405 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Wenningmann and J. P. Dilger The Kinetics of Inhibition of Nicotinic Acetylcholine Receptors by (+)-Tubocurarine and Pancuronium Mol. Pharmacol., October 1, 2001; 60(4): 790 - 796. [Abstract] [Full Text] [PDF] |
||||